Show simple item record

dc.contributor.authorClarke, Noel W
dc.contributor.authorArmstrong, AJ
dc.contributor.authorThiery-Vuillemin, A
dc.contributor.authorOya, M
dc.contributor.authorYe, DW
dc.contributor.authorMateo, J
dc.contributor.authorGoessl, CD
dc.contributor.authorKang, JY
dc.contributor.authorLiu, S
dc.contributor.authorSaad, F
dc.date.accessioned2019-11-19T16:01:09Z
dc.date.available2019-11-19T16:01:09Z
dc.date.issued2019en
dc.identifier.citationClarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Ye D, Mateo J, et al. PROPEL: a randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2019;37(7_suppl):TPS340-TPS.en
dc.identifier.doi10.1200/JCO.2019.37.7_suppl.TPS340en
dc.identifier.urihttp://hdl.handle.net/10541/622474
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/ 10.1200/JCO.2019.37.7_suppl.TPS340en
dc.titlePROPEL: a randomized, phase Ill trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Christie and Salford Royal Hospitals, Manchesteren
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record